MAPT and Alzheimer disease: Our results indicate that by using p-tau/tau ratios, we may be able to reduce the variability in plasma p-tau levels driven by impaired kidney function and consequently such ratios are more robust measures of brain p-tau pathology in individuals with both early- and later-stage AD.